Fresenius SE & Co KGAA O.N. (FREG)

44.385
-1.780(-3.86%)
  • Volume:
    2,306,084
  • Bid/Ask:
    44.360/44.410
  • Day's Range:
    43.840 - 45.850
  • Type:Equity
  • Market:Germany
  • ISIN:DE0005785604
  • WKN:578560

FREG Overview

Prev. Close
44.385
Day's Range
43.84-45.85
Revenue
36.13B
Open
45.83
52 wk Range
31.03-46.525
EPS
3.03
Volume
2,306,084
Market Cap
25.75B
Dividend (Yield)
0.88
(1.93%)
Average Volume (3m)
1,274,341
P/E Ratio
15.25
Beta
1.15
1-Year Change
2.32%
Shares Outstanding
557,541,659
Next Earnings Date
29 July 2021
What is your sentiment on Fresenius SE & Co KGAA O.N.?
or
Market is currently closed. Voting is open during market hours.

Fresenius SE & Co KGAA O.N. News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellBuy
Technical IndicatorsStrong SellStrong SellStrong SellSellStrong Buy
SummaryStrong SellStrong SellStrong SellSellStrong Buy

Fresenius SE & Co KGAA O.N. Company Profile

Fresenius SE & Co KGAA O.N. Company Profile

Employees
310842
Market
Germany

Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune diseases and oncology; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operated 89 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 46 hospitals, 70 outpatient clinics, and approximately 300 risk prevention centers in Spain. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project consulting and development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.